Soligenix Advances Orphan Drug Strategy with HyBryte for Rare Skin Cancer Treatment

Soligenix Inc. is advancing a differentiated approach to orphan drug development, emphasizing a de-risked model focused on patient safety and capital efficiency, as highlighted in a recent citybiz feature. The company’s lead candidate, HyBryte, targets cutaneous T-cell lymphoma using visible light activation rather than traditional chemotherapy or UV-based therapies, with clinical data indicating faster response times and a favorable safety profile.

The company is nearing completion of a confirmatory Phase 3 study for HyBryte, with interim analysis expected in early 2026 and top-line results later in the year, alongside supportive data showing strong patient response rates. This approach also supports potential at-home treatment through telehealth-enabled delivery, potentially improving patient access and convenience for those with this rare cancer.

Soligenix’s broader strategy leverages regulatory incentives for orphan diseases and more than $60 million in non-dilutive funding to advance multiple pipeline candidates. The company’s development programs include potential applications in psoriasis and autoimmune conditions, positioning the organization for continued growth in rare disease therapeutics. The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX.

The company’s Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin into psoriasis and first-in-class innate defense regulator technology for inflammatory diseases.

Soligenix’s Public Health Solutions business segment includes development programs for vaccine candidates targeting various threats, supported with government grant and contract funding from agencies including the National Institute of Allergy and Infectious Diseases. The development of these vaccine programs incorporates the use of proprietary heat stabilization platform technology known as ThermoVax. For more information about the communications platform that distributed this information, please visit https://www.BioMedWire.com.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Soligenix Advances Orphan Drug Strategy with HyBryte for Rare Skin Cancer Treatment.

The post Soligenix Advances Orphan Drug Strategy with HyBryte for Rare Skin Cancer Treatment appeared first on citybuzz.